[The Use of Platinum-Based Chemotherapy for Esophageal Cancer Patients with Impaired Renal Function].
Gan To Kagaku Ryoho
; 50(13): 1783-1785, 2023 Dec.
Article
in Ja
| MEDLINE
| ID: mdl-38303206
ABSTRACT
INTRODUCTION:
The key drugs of first-line chemotherapy for metastatic esophageal cancer are 5-FU and cisplatin(CF). However, the treatment strategy for unfit patients of CF regimen remains controversial.METHODS:
Fifty patients who received first-line chemotherapy including platinum-containing drug for metastatic esophageal cancer between 2018-2022 at Osaka National Hospital were analyzed. They were divided into 4 groups according to estimated creatinine clearance(Ccr) at the beginning of the treatment; Group A(over 60 mL/min)31 patients, Group B(50-59 mL/min)12 patients, Group C(30-49 mL/min)5 patients, and Group D(under 30 mL/min)2 patients. The background and treatment outcome data of each group were retrieved retrospectively and compared.RESULTS:
Group B, C, D had more elderly patients than Group A. Each Group B, C, D included 1 patient who received FOLFOX regimen. More than half patients in Group B, C, D reduced the dose of CDDP and the initial dose of CDDP was adequately reduced according to Ccr. Group B, C, D had more patients with decreased renal function over Grade 1 than Group A. The clinical response rate was Group A 65%, Group B 42%, Group C 60%, Group D 50%, respectively. There were no patients who ceased the treatment due to adverse events.CONCLUSION:
Adequate dose reduction of CF regimen would become more important in the era that only CF regimen can be a partner of immune-checkpoint inhibitor.
Search on Google
Database:
MEDLINE
Main subject:
Platinum
/
Esophageal Neoplasms
Type of study:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Aged
/
Humans
Language:
Ja
Journal:
Gan To Kagaku Ryoho
Year:
2023
Type:
Article